Joe Biden Comes to Town
20 hours ago
Adam said,
only fools rush in
but he couldn’t help
falling in love with U(naue)
What the hey
since the pool is “thin”
We’ll risk it all falling in love with U(naue)...
Like a river flows, surely to the sea
Puharic’s gone and plucked a candidate from a tree..
He’ll lose this hand, like the other races, too
He’ll risk it all falling in love with U(naue).
Like a river flows, surely to the sea
Puharic’s failure grows, somethings aren’t meant to be..
Come this June, the party’s changing, too
For we can’t watch Puharic splitting us in two
for we won’t join falling in love with U(naue).
Ten years ago John Crowley was heading up the ladder of success. He had earned a bachelor's degree from Georgetown's School of Foreign Service in 1989, a law degree from Notre Dame in 1992 and an MBA from Harvard in 1997, all leading to a job he enjoyed in management consulting in San Francisco. But one day in March of 1998, in the office of his daughter's pediatrician, the trajectory of his life took an unexpected and frightful turn.
The doctor told Crowley and his wife, Aileen, that tests indicated their 15-month-old daughter, Megan, was suffering from Pompe disease, a rare genetic disorder related to muscular dystrophy that afflicts fewer than 10,000 people worldwide. The couple had their first inkling that something might be seriously wrong with Megan when she was 5 months old. By that age, most infants begin to roll over and crawl. Their daughter had difficulty turning over and never even attempted to crawl. They also noticed she had trouble swallowing.
The doctor said Megan's problems were due to a genetic enzyme deficiency that made her body store a sticky substance in her muscles, eventually destroying them. By the age of 2, afflicted children usually require a respirator to breathe, by 4 they are paralyzed and by 5 most die from respiratory failure. There was no cure, no treatment, he said.
The news left the couple reeling. When it seemed things couldn't get worse, they learned a few months later that the second of their three children, Patrick, who was a year younger than Megan, also suffered from the disease. Once they got over the shock of the diagnoses, the family moved to New Jersey to be close to doctors specializing in Pompe disease, John took a job with Bristol-Myers Squibb, and the Crowleys resolved to do whatever they could to find a cure for their children.
Frustrated with the slow pace of Pompe research in the pharmaceutical industry, John left his job in 2000 to head up Novazyme Pharmaceuticals, Inc., a tiny biotech firm that had a promising therapeutic approach for Pompe disease. What it didn't have was the funding to develop that therapy.
The company desperately needed Crowley's skills. In his first week as CEO, he was horrified to discover the firm had only $37,000 in its checking account. To keep the company temporarily afloat, Crowley and his wife took out a second mortgage on their New Jersey home for $100,000. Within a year, John had raised $27 million in venture capital for the firm and brokered a deal, selling Novazyme to a competitor, Genzyme Corporation, for $137.5 million. With the acquisition, Crowley was named a senior vice president and head of Genzyme's Pompe program.
In a cruel irony, just when scientists finally had a test version of a drug ready, the Crowley children were disqualified from the initial trial. "That was more than frustrating," John recalls. "Even though the FDA was comfortable with Megan and Patrick being part of the trial, the hospital's Internal Review Board rejected their application because they claimed it was a conflict of interest for me to be an executive of the company and have my children treated."
Fortunately, a few months after the first drug trial, another hospital accepted Megan and Patrick and they became the 27th and 28th patients in the world to be treated with the drug called Myozyme. To make sure his children could qualify for treatment, Crowley resigned from Genzyme. Since then his daughter and son have received twice-weekly infusions of the drug.While the therapy is not a cure, it has improved their condition. Most dramatically, the drug has reduced the size of their dangerously enlarged hearts, and Megan and Patrick, now age 10 and 9 respectively, have surpassed their initial life expectancy.
"The kids are doing pretty well," John says. "The medicine has stabilized them, and they're able to go to public school." Their health remains fragile, however, and they still require wheelchairs to move, ventilators to breathe and food pumps to eat.
In a hopeful recent development, this past December Amicus Therapeutics, a new biotech firm that John has headed since 2005, began clinical trials of a novel drug for Pompe disease. Instead of replacing the defective enzyme, which is the conventional approach, the Amicus drug binds with the patient's own enzyme, tricking the body into thinking it is "good" and causing it to do its intended job.
John and Aileen's efforts for their children have not gone unnoticed by the media. Besides being the subject of countless newspaper and TV interviews, a critically acclaimed book, The Cure: How a Father Raised $100 Million -- and Bucked the Medical Establishment -- in a Quest to Save His Children, was published last fall. Written by the Pulitzer-Prize-winning Wall Street Journal reporter Geeta Anand, the book is the basis for a Hollywood movie about the Crowleys. The film, which will star Harrison Ford, is slated for release in 2008.
“Your daughter is some little fighter,” Dr. Hofley said softly, shaking his head and looking from John Crowley to his wife, Aileen. “I wish she would just close her eyes and rest, but she’s determined to stay awake.”
As they entered the hospital’s Pediatric Intensive Care Unit, John and Aileen saw Megan lying on her back, her eyes open, scanning the room. Her eyes settled on them and immediately filled with tears. Aileen rushed over to kiss her.
John, still incredulous that Megan had lived through the morning, rubbed her matted hair gently. “All right, kid,” he said, staring gravely into her big dark eyes. “If you want to fight, we’ll fight too.”
John F. Crowley
President and Chief Executive Officer
Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.
Mr. Crowley is involved with several charitable and community organizations, including serving on the Board of Directors of St. Peter's University Health Care System. Mr. Crowley's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show on CNN. In 2006, Geeta Anand, Pulitzer prize winning writer for The Wall Street Journal, authored a book on Mr. Crowley entitled "The Cure: How a Father Raised $100 Million- and Bucked the Medical Establishment- in a Quest to Save His Children." (www.thecurebook.com).
Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).
Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.
Statement from Mayor DiBella
Mayor Joseph M. DiBella
Township of Howell, NJ
March 18, 2008
After weeks of thoughtful consideration and discussions with my wife and children, I have elected not to seek a second term as your Mayor. This was not an easy decision to reach because I sincerely enjoy being Mayor of our wonderful community. For me this was a difficult and deeply personal decision. However, having served as a councilman for two years and now nearly four as your Mayor, I believe it is time to step aside for now and allow others to have the awesome privilege of serving Howell Township.
I am making this announcement now because the filing deadline for re-election is upon us and I wanted the matter resolved so that I may focus exclusively on fulfilling the balance of my term without any personal or partisan distractions.
As I reflect upon my time in office I am humbled by the incredible privilege you have bestowed upon me to lead our community. There is no calling more important or more fulfilling as public service and I am eternally grateful for the opportunity this community has given me. Being Mayor of Howell Township has been one of the highlights of my life and the experiences I have endured will stay with me forever.
Without having to spend time on seeking re-election I shall now be able to devote all of my time and efforts towards carrying out the balance of my term this year with absolute clarity and focus. 2008 has only just begun and we have many daunting and complex issues to overcome as a community.
While I am proud of the many things I have been a part of these last nearly six years I know there is still much to be done. Accordingly, I remain completely focused and committed towards fulfilling my duties as Mayor and doing everything I can to make our community a better place. Thank you.
_________________
Most Respectfully
Joseph M. DiBella
HACKENSACK, NJ – State Senator Joe Pennacchio won tonight's Bergen County Republican Convention by an overwhelming vote of 351 to 79.
Since last week's victories in Hunterdon and Union Counties, Joe Pennacchio's campaign for United States Senate has continued to gain momentum. The Middlesex County Republican Screening Committee endorsed Joe Wednesday night.
As organizational and rank-and-file support continue to build, Republican voters throughout the state are embracing Joe Pennacchio's conservative message of lower taxes, less government, and individual liberty.
Joe Pennacchio is a New Jersey State Senator representing the 26th Legislative District.
Visit www.jerseyjoe08.com for more information on Joe Pennacchio's candidacy for the United States Senate.
“Ann Estabrook ran for all the right reasons and is ending her campaign for the right reason. I spoke to Ann last night and know that her decision to end her candidacy was easy from the standpoint of her health and well-being, but still difficult for a person who has within her a passion to give and fight. Like all Republicans, I thank Ann for her willingness to give something back to her country. I wish Ann many more years of good health and look forward to her continued involvement in our party.
This race is about who is best up for the demands of the job. Which candidate is best able to endure the rigors of a campaign and who is up for the demands of serving every day, for six years, to fight for New Jersey? Senator Lautenberg is 84 years old and has served in the Senate for nearly 25 years. During that time, New Jerseyans have watched our taxes increase and our share of the federal pie shrink. It is time for a change. Frank Lautenberg had his chance and his best days, which really weren’t very good, are behind him.”